Category: BUHLMANN Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Faecal Calprotectin Predicts Endoscopic and Histological Activity

BÜHLMANN fCAL® ELISA Citation Lara Hart et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis, Journal of Crohn's and Colitis, Volume 14, Issue 1, January 2020, DOI: doi.org/10.1093/ecco-jcc/jjz107 READ CITATION BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use. Health Canada License: 80726 This citation describes applications that are outside of
Continue Reading

Quantum Blue® Anti-Adalimumab: Development and evaluation of a rapid test

BÜHLMANN Quantum Blue® Anti-Adalimumab Citation: B Ricken, M Schneider, F Bantleon, S Velayutham, D Trapani, J Afonso, F Magro, A Abel. Quantum Blue® Anti-Adalimumab: Development and evaluation of a point of care rapid test for measuring anti-adalimumab antibodies in human serum. ECCO 2019 P153. DOI: doi.org/10.1093/ecco-jcc/jjy222.277 BÜHLMANN Quantum Blue® Anti-Adalimumab is for Research Use Only in
Continue Reading

ECCO 2020 Poster – IBDoc Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)

IBDoc® Citation: Avery, P. et. al. N05: IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH).  ECCO 2020, Feb 12-15. Highlights from this Publication “ …This data also helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments....” Read Citation Health
Continue Reading

ECCO 2020 Poster: IBD Home at GHP Stockholm Gastro Center in Sweden

IBDoc® Citation: S. Jäghult et. al.  N08: IBD Home at GHP Stockholm Gastro Center in Sweden. ECCO 2020, Feb 12-15. Highlights from this Publication “ …The majority (n = 24) stated that it was easy to install IBD Home. A total of nine patients noted that their participation in their own health care had increased...” “
Continue Reading

ECCO 2020 Poster – An evaluation of the impact of IBDoc

BÜHLMANN IBDoc®: Sugrue, K. et al.  N12: An evaluation of the impact of IBDoc in clinical practice 5 years after introduction.  ECCO 2020, Feb 12 – 15, 2020. Vienna, Austria. Highlights from this Publication “This study shows the benefits of using IBDoc® in clinical practice. It is central to facilitating a fast track system for patients
Continue Reading

Quantum blue anti-infliximab: development and evaluation of a rapid test

BÜHLMANN Quantum Blue® Anti-Infliximab Citation: F. I. Bantleona, M. Schneidera, B. Rickena, S. Velayuthama, D. Trapania, J. Afonsob, F. Magrob, A. P. Abel. Quantum Blue® Anti-Infliximab: Development and evaluation of a point of care rapid test for measuring anti-infliximab antibodies in human serum. ECCO 2019 P202. DOI: 10.1093/ecco-jcc/jjy222.326.  Highlight from this Publication “...Quantum Blue® Anti-Infliximab test
Continue Reading

IBDoc Key Literature List

IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay!   View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading

100 BÜHLMANN Calprotectin Publications

BÜHLMANN launched its first fecal calprotectin assay over 10 years ago and since then has developed into THE CALPROTECTIN COMPANY with the highest quality standards. The offerings include the FDA 510(k) cleared BÜHLMANN fCAL® ELISA, the FDA 510(k) cleared automated BÜHLMANN fCAL® turbo (in combination with CALEX® Cap fecal extraction device) for testing on most
Continue Reading

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain.  P1750.  Read Citation BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading